Delayed stem cell therapy following heart attack is safe but not effective
December 14th, 2011
Stem cells obtained from bone marrow, known as BMCs, can be safely injected into people 2-3 weeks following a heart attack, reports a new clinical trial supported by the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. However, while safe, the BMCs did not improve heart function six months after their administration.
Related posts:
- Information about the quality of the care hospitals give patients who are being treated for a heart attack information about the quality of the care hospitals give patients who are being treated for a heart attack...
- Scientists find approach to enhance and prolong immune attack against tumor cells Investigators have identified a new class of human immune cells that behave like stem cells. These cells, a subtype of T lymphocytes, which comprise a small fraction of white blood cells, may prove more effective than any previously reported type of T cell for treating tumors. The study, by scientists at the National Cancer Institute […]...
- MedicareCard.com – Adding Coronary Calcium Score to Traditional Risk Factors Improves Risk Assessment for Heart Disease Including a coronary artery calcium score in a risk assessment for future heart disease events, such as heart attacks, provides a better estimate in some populations than a standard coronar...
- MedicareCard, Newer Heart Surgery, Infants Offers First-Year Survival Benefit over Traditional Procedure Infants born with a severely underdeveloped heart who undergo a newer surgical procedure are more likely to survive their first year and not require a heart transplant than those who have a more traditional surgical procedure, according to a report by researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), which is part […]...
- Medicare Card, Stroke Prevention Study, Children with Sickle Cell Anemia, Iron Overload Stopped Early The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment....
- Possible alternate therapy for adults with poorly controlled asthma A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health....
- MedicareCard.com – NIH Study Confirms Location of Stem Cells Near Cartilage-Rich Regions in Bones Working with mice, a team of researchers has pinpointed the location of bone generating stem cells in the spine, at the ends of shins, and in other bones. The team also has identified factors that control the stem cells’ growth. The research was conducted at the National Institutes of Health and other institutions....
- NIH-funded study finds new possible risk factor of heart disease, Medicare NIH-funded study finds new possible risk factor of heart disease, Medicare...
- Clinical trial stopped on combination cholesterol treatment The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular […]...
- Standard aplastic anemia therapy improves patient outcomes better than newer version A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than Thymoglobulin, a similar but reportedly more potent treatment. The research was carried out by the National Heart, Lung and Blood Institute (NHLBI), part […]...
- MedicareCard.com encourages women to take charge of their heart health On Wednesday, Feb. 9, 2011, the National Heart, Lung, and Blood Institute’s (NHLBI) The Heart Truth campaign will once again bring the Red Dress to life on the runway at Mercedes-Benz Fashion Week in New York City, with the debut of the Red Dress Collection 2011. For the first time, the event will be held […]...
- Study of youth to seek origins of heart disease among African-Americans Researchers supported by the National Institutes of Health are undertaking a preliminary study to identify the early origins of heart disease among African-Americans. The new feasibility study will enroll children and grand children of participants taking part in the largest study of heart disease risk factors among African-American adults, the Jackson Heart Study (JHS), in […]...
- Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns....
- Uterine stem cells used to treat diabetes in mice Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes....
- Medicare, Medicare Card, Study Finds Two Sling Surgeries, Equally Effective for Bladder Control in Women Two common operations for stress urinary incontinence (SUI) help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine […]...
Posted in MedicareCard Replacement | Tags: MEDICARE CARD REPLACEMENT